UroGen Pharma Ltd (URGN) Short-Term Debt to Equity
UroGen Pharma Ltd. (URGN) develops innovative methods for combating oncology. This price chart illustrates the asset's dynamics, where the individual debt-to-equity ratio stands at 0.00. The business relies on a unique therapeutic gel that has created a monopoly in urology, despite the risks of government price regulation. Meanwhile, drug production is fully delegated to external contractors through strict agreements.
%3A%20Short-Term%20Debt%20to%20Capital%20Ratio&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_URGN_-_UroGen-Pharma-Ltd._-_Short-Term-Debt-to-Capital-Ratio "UroGen - URGN Short-Term Debt to Capital (period 07/04/2022 - 11/01/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for urogen.com (URGN)
- stock quotes and analyst forecast:
- market capitalization details:
- balance sheet equity data:
- business debt structure and liquidity details:
Debt to Equity UroGen Pharma Ltd.|URGN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio UroGen Pharma|URGN - Aggregate Debt Obligations|Debts to Book Capitalization UroGen Pharma Ltd|URGN - Company Long-Term Liabilities|Company Current Liabilities UroGen Pharma|Quick Liquidity urogen.com
- earnings and market ratios statistics:
Fundamental valuation:UroGen
Fundamental asset selection requires solvency analysis via the ratio of short-term liabilities to equity to eliminate devaluation risks. The current value of 0.00 reflects the share of loans under one year within the capital structure of UroGen Pharma Ltd. (URGN), which is critical when financing marketing for gel sales; therefore, the short-term debt-to-equity trend confirms the stability of the issuer's financial cushion.
Competitors of UroGen Pharma Ltd.
Short-Term Debt to Capital ONC|Short-Term Debt to Capital Halozyme Corp (HALO)|Short-Term Debt to Equity Revolution Medicines RVMD|AAPG: Short-Term Debt to Capital Ratio|CG Oncology - Short-Term Debt to Capital|Bicara Therapeutics Inc (BCAX) - Short-Term Debt to Equity Ratio|PSNL: Short-Term Debt to Capital|Current Liabilities to Capital Erasca Oncology (ERAS)|Short-Term Debt to Equity Delcath Systems, Inc.|YMAB: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio AURA (Aura Biosciences)|CADL (candeltx.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ARAY (Accuray Inc.)|SLS - Short-Term Debt to Equity Ratio|ACTU: Short-Term Debt to Equity Ratio|CTOR - Short-Term Debt to Capital|tuhurabio.com (HURA) - Short-Term Debt to Equity|Protara Therapeutics Inc - Ratio of Short-Term Indebtedness to Capital|FATE (Fate Therapeutics Corp) - Short-Term Debt to Capital|Current Liabilities to Capital Aadi Bio WHWK|Short-Term Debt to Equity Ratio TCRX (TScan Therapeutics)|Short-Term Debt to Capital championsoncology.com (CSBR)|Short-Term Debt to Equity XBiotech XBIT|Ratio of Short-Term Indebtedness to Capital CVM|OSTX - Short-Term Debt to Equity|Current Liabilities to Capital Radiopharm Theranostics Ltd|ARTV: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Adlai Nortye ANL|VERU (Veru) - Short-Term Debt to Capital|Current Liabilities to Capital Tempest Therapeutics Inc TPST|Short-Term Debt to Equity Xilio Therapeutics, Inc. (XLO)|renovarobio.com - Short-Term Debt to Capital Ratio|Mural Oncology - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital KAPA|OKUR - Short-Term Debt to Equity|Current Liabilities to Equity GDTC|CRIS: Short-Term Debt to Capital|Apollomics - Ratio of Short-Term Indebtedness to Capital|THAR (Tharimmune, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Advanced Biomed Corp|Short-Term Debt to Equity Genprex (GNPX)|CLDI (calidibio.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Sunshine Biopharma SBFM|XBIO - Short-Term Debt to Equity Ratio|Salarius Pharmaceuticals - Short-Term Debt to Capital|PPBT - Short-Term Debt to Capital|AONC (aoncology.com) - Short-Term Debt to Equity Ratio|BeiGene Ltd. - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Checkpoint Therapeutics, Inc|Short-Term Debt to Equity ELEV|Short-Term Debt to Equity Ratio ICAD (iCAD, Inc.)|Short-Term Loans to Capital Ratio IKNA|Short-Term Debt to Capital NTBL (Notable Labs)|VIRX: Short-Term Debt to Capital Ratio|MOR: Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient NAYA Biosciences Corp NAYA|AAPGV (Ascentage Pharma Group) - Short-Term Debt to Equity Ratio